Sage Therapeutics Inc (SAGE) - Financial and Strategic SWOT Analysis Review

Sage Therapeutics Inc (SAGE) - Financial and Strategic SWOT Analysis Review


  • Products Id :- GDPH357890FSA
  • |
  • Pages: 54
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Sage Therapeutics Inc (SAGE)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Sage Therapeutics Inc (Sage) is a clinical-stage biopharmaceutical company that discovers and develops therapeutics and medicines for central nervous system (CNS) disorders. It develops drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The company has a portfolio of product candidates with the focus of being able to modulate two critical CNS receptor systems, NMDA and GABA. The company's pipeline products include Brexanolone, SAGE-217, SAGE-324 and SAGE-718 compounds for use in treatment of indications such as postpartum depression, major depressive disorders, bipolar depression, Parkinson's disease, insomnia, epileptiform disorders and NMDA hypofunction. Sage is headquartered in Cambridge, Massachusetts, the US.

Sage Therapeutics Inc Key Recent Developments

May 03,2018: Sage Therapeutics Announces First Quarter 2018 Financial Results and Provides Update on Pipeline and Progress toward Launch Readiness

Feb 22,2018: Sage Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results

Jan 08,2018: Sage Therapeutics to Provide Pipeline Update at J.P. Morgan Healthcare Conference and Outline Key 2018 Initiatives to Support Planned Evolution to a Fully-Integrated Commercial Biopharmaceutical Company

Nov 08,2017: Sage Therapeutics Appoints Asha Nayak, M.D., Ph.D., to Board of Directors

Nov 02,2017: Sage Therapeutics Announces Third Quarter 2017 Financial Results and Provides Pipeline Update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

Sage Therapeutics Inc-Key Facts 6

Sage Therapeutics Inc-Key Employees 7

Sage Therapeutics Inc-Key Employee Biographies 8

Sage Therapeutics Inc-Major Products and Services 10

Sage Therapeutics Inc-History 11

Sage Therapeutics Inc-Company Statement 12

Sage Therapeutics Inc-Locations And Subsidiaries 14

Head Office 14

Other Locations & Subsidiaries 14

Section 2-Company Analysis 15

Company Overview 15

Sage Therapeutics Inc-Business Description 16

R&D Overview 16

Sage Therapeutics Inc-SWOT Analysis 17

SWOT Analysis-Overview 17

Sage Therapeutics Inc-Strengths 17

Sage Therapeutics Inc-Weaknesses 18

Sage Therapeutics Inc-Opportunities 19

Sage Therapeutics Inc-Threats 20

Sage Therapeutics Inc-Key Competitors 21

Section 3-Company Financial Ratios 22

Financial Ratios-Capital Market Ratios 22

Financial Ratios-Annual Ratios 23

Performance Chart 25

Financial Performance 25

Financial Ratios-Interim Ratios 26

Financial Ratios-Ratio Charts 27

Section 4-Company's Lifesciences Financial Deals and Alliances 28

Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28

Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 29

Sage Therapeutics Inc, Recent Deals Summary 30

Section 5-Company's Recent Developments 31

May 03, 2018: Sage Therapeutics Announces First Quarter 2018 Financial Results and Provides Update on Pipeline and Progress toward Launch Readiness 31

Jan 08, 2018: Sage Therapeutics to Provide Pipeline Update at J.P. Morgan Healthcare Conference and Outline Key 2018 Initiatives to Support Planned Evolution to a Fully-Integrated Commercial Biopharmaceutical Company 34

Nov 08, 2017: Sage Therapeutics Appoints Asha Nayak, M.D., Ph.D., to Board of Directors 36

Nov 08, 2017: Sage Therapeutics Appoints Asha Nayak, M.D., Ph.D., to Board of Directors 37

Nov 02, 2017: Sage Therapeutics Announces Third Quarter 2017 Financial Results and Provides Pipeline Update 38

Aug 03, 2017: Sage Therapeutics Announces Second Quarter 2017 Financial Results and Provides Pipeline Update 41

Jul 10, 2017: Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 43

May 09, 2017: Sage Therapeutics Announces First Quarter 2017 Financial Results and Provides Pipeline Update 44

Apr 24, 2017: Sage Therapeutics Appoints Michael Cloonan as Chief Business Officer and Expands Executive Team 47

Feb 23, 2017: Sage Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 48

Section 6-Appendix 50

Methodology 50

Ratio Definitions 50

About GlobalData 54

Contact Us 54

Disclaimer 54

List of Figures

Sage Therapeutics Inc, Performance Chart (2013-2017) 25

Sage Therapeutics Inc, Ratio Charts 27

Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28

Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 29

List of Tables

Sage Therapeutics Inc, Key Facts 6

Sage Therapeutics Inc, Key Employees 7

Sage Therapeutics Inc, Key Employee Biographies 8

Sage Therapeutics Inc, Major Products and Services 10

Sage Therapeutics Inc, History 11

Sage Therapeutics Inc, Subsidiaries 14

Sage Therapeutics Inc, Key Competitors 21

Sage Therapeutics Inc, Ratios based on current share price 22

Sage Therapeutics Inc, Annual Ratios 23

Sage Therapeutics Inc, Annual Ratios (Cont...1) 24

Sage Therapeutics Inc, Interim Ratios 26

Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28

Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 29

Sage Therapeutics Inc, Recent Deals Summary 30

Currency Codes 50

Capital Market Ratios 50

Equity Ratios 51

Profitability Ratios 51

Cost Ratios 52

Liquidity Ratios 52

Leverage Ratios 53

Efficiency Ratios 53

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Supernus Pharmaceuticals Inc

Marinus Pharmaceuticals Inc

Edge Therapeutics Inc

Sage Therapeutics Inc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts

select a license
Single User License
USD 125 INR 8651
Site License
USD 250 INR 17303
Corporate User License
USD 375 INR 25954

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com